PI3K inhib 
Welcome,         Profile    Billing    Logout  
 69 Companies  60 Products   60 Products   344 Diseases   410 Trials   13287 News 


«12345678910111213...247248»
  • ||||||||||  cisplatin / Generic mfg.
    Journal:  Chaetocin, a Natural Inhibitor of Transketolase, Suppresses the Non-Oxidative Pentose Phosphate Pathway and Inhibits the Growth of Drug-Resistant Non-Small Cell Lung Cancer. (Pubmed Central) -  Apr 14, 2025   
    In this paper, firstly, chaetotocin significantly inhibited the viability and migration of cisplatin-resistant non-small cell lung cancer (NSCLC) cells and inhibited the xenograft growth of nude mice...Additionally, the muti-omics analysis and RNA interference suggested that chaetocin can inhibit the PI3K/Akt signaling pathway through TKT. In conclusion, chaetocin could directly bind to TKT, inhibiting its enzyme activity and expression, which interfered with intracellular metabolism and oxidation-reduction balance, and then regulated the PI3K/Akt signaling pathway to inhibit the growth of NSCLC and induce apoptosis.
  • ||||||||||  arsenic trioxide / Generic mfg.
    Journal:  Synergic effect of the combination of isoliquiritigenin and aresnic trioxide in HepG2 liver cancer cells. (Pubmed Central) -  Apr 13, 2025   
    Finally, we observed that combination treatment effectively suppressed tumor growth in nude mice xenograft model through induction of intrinsic apoptosis and inhibition of PI3K/Akt/mTOR pathway. In conclusion, the findings of this study suggest that both drugs work synergistically to exert anti-tumor effect in HCC, both in-vitro and in-vivo and could offer novel strategy for liver cancer treatment.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Preclinical, Journal:  Therapeutic Effects and Mechanisms of Alcohol Extracts from Polygala fallax Hemsl on Endometriosis in Rats. (Pubmed Central) -  Apr 13, 2025   
    Additionally, in combination therapy, ae-PFH significantly enhanced therapeutic effects of mifepristone or exosomes derived from umbilical cord mesenchymal stem cells. These findings indicate that ae-PFH presents a promising medical method for the treatment of endometriosis, exhibiting innovative potentiality for combination therapy.
  • ||||||||||  LY294002 / Eli Lilly
    Preclinical, Journal:  TREM2 promotes hippocampal neurogenesis through regulating microglial M2 polarization in APP/PS1 mice. (Pubmed Central) -  Apr 11, 2025   
    Taken together, these findings indicated that upregulation of TREM2 activated the PI3K/Akt signaling pathway to promote microglial M2 polarization and led to the secretion of more BDNF, accompanied by an improved hippocampal neurogenesis and spatial cognitive function in APP/PS1 mice. Thus, TREM2 might be a promising target for the treatment of neurodegenerative disease.
  • ||||||||||  bleomycin / Generic mfg.
    Review, Journal:  Classification, diagnosis, and management of orbital venous-lymphatic malformations: Current state-of-the-art. (Pubmed Central) -  Apr 11, 2025   
    Sclerosing agents such as bleomycin and pingyangmycin typically yield effective treatment outcomes with relatively favorable safety profiles...Emerging treatments targeting molecular pathways, including PI3K inhibitors and anti-VEGF therapies, show promise in refractory cases. As our understanding deepens, clinicians can now offer more personalized interventions that consider factors such as lesion location, extent, architecture, and hemodynamic characteristics, thereby minimizing morbidity and optimizing clinical and aesthetic outcomes.
  • ||||||||||  Truqap (capivasertib) / Otsuka, AstraZeneca
    Journal:  Capivasertib: First Approved AKT inhibitor for the Treatment of Patients with Breast Cancer. (Pubmed Central) -  Apr 10, 2025   
    It is used for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with at least one alteration on PIK3CA/AKT1/PTEN. In this short perspective, Capivasertib's physicochemical properties, synthesis, mechanism of action, binding mode, pharmacokinetics, drug interaction studies, and treatment-emergent adverse events are discussed.
  • ||||||||||  Journal:  Dyr726, a brain-penetrant inhibitor of PI3K?, Type III receptor tyrosine kinases, and WNT signaling. (Pubmed Central) -  Apr 8, 2025   
    Phospho-proteomic, structural, and target engagement analyses, combined with in vitro , in vivo efficacy, and pharmacokinetic studies reveal that Dyr726 is a brain-penetrant small molecule which effectively reduces tumour volume and extends survival of murine orthotopic models. Our current work establishes a first-in-class brain penetrant small molecule mKI which simultaneously antagonize the PI3K-AKT-mTOR and WNT pathways in preclinical cancer stem cell cultures, adult and pediatric primary organoids, and orthotopic murine models with positive efficacy in combination with clinical standard of care.
  • ||||||||||  Review, Journal:  Can we really protect the ovary from chemotherapy damage? (Pubmed Central) -  Apr 5, 2025   
    Although promising results have been observed in vitro and in vivo in rodent models, further investigations to bypass their limitations are needed to confirm their efficacy and safety. These challenges include the non-interference with anti-tumoral effect of chemotherapy and the specificity of fertoprotective agents to ovaries.
  • ||||||||||  Piqray (alpelisib) / Novartis, Zarnestra (tipifarnib) / Kura Oncology
    Journal, PD(L)-1 Biomarker, IO biomarker:  Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers. (Pubmed Central) -  Apr 3, 2025   
    These findings underscore the critical role of antitumor immunity, particularly CD8+T cell activity, in the efficacy of tipifarnib alone and in combination with alpelisib. The triple combination of tipifarnib, alpelisib, and anti-PD1 treatment showed superior antitumor activity and extended survival in preclinical models, suggesting its potential as a therapeutic strategy for HNSCC patients with HRAS- and PIK3CA-mutation.
  • ||||||||||  Journal:  Isolation of proteins on chromatin (iPOC) reveals signaling pathway-dependent alterations in the DNA-bound proteome. (Pubmed Central) -  Apr 3, 2025   
    Our results show distinct dynamics of the DNA-bound proteome upon selective inhibition of PI3K, AKT, or mTOR, and we provide evidence how this signaling cascade regulates the DNA-bound status of SUZ12, thereby modulating H3K27me3 levels. Collectively, iPOC is a powerful approach to study the composition of the DNA-bound proteome operating downstream of signaling cascades, thereby both expanding our knowledge of the mechanism of action of the pathway, and unveiling novel chromatin modulators that can potentially be targeted pharmacologically.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
    Trial completion, Enrollment change:  Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) -  Apr 3, 2025   
    P1/2,  N=28, Completed, 
    Collectively, iPOC is a powerful approach to study the composition of the DNA-bound proteome operating downstream of signaling cascades, thereby both expanding our knowledge of the mechanism of action of the pathway, and unveiling novel chromatin modulators that can potentially be targeted pharmacologically. Active, not recruiting --> Completed | N=106 --> 28